Cancer experts offer healthy dose of skepticism toward hype over antiangiogenesis agents.
Phillips
P
P
D043168:Angiostatins; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001808:Blood Vessels / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003094:Collagen / Q000627:therapeutic use; D043169:Endostatins; D016228:Endothelial Growth Factors / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D006801:Humans; D008222:Lymphokines / Q000627:therapeutic use; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010446:Peptide Fragments / Q000627:therapeutic use; D010958:Plasminogen / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000970:Antineoplastic Agents; D043169:Endostatins; D016228:Endothelial Growth Factors; D008222:Lymphokines; D010446:Peptide Fragments; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D043168:Angiostatins; D010958:Plasminogen; D003094:Collagen; D008666:Metalloendopeptidases